Glibenclamide-13C6

Glibenclamide-13C6 (Glyburide-13C6) is 13C labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) [3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Product Specifications

Product Name Alternative

Glyburide-13C6

UNSPSC

12352005

Target

Autophagy; CFTR; Isotope-Labeled Compounds; Mitochondrial Metabolism; P-glycoprotein; Potassium Channel

Related Pathways

Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Smiles

ClC1=CC(C(NCCC2=CC=C(S(NC(N[13CH]3[13C][13CH2][13CH2][13CH2][13CH2]3)=O)(=O)=O)C=C2)=O)=C(OC)C=C1

Molecular Formula

C17 13C6H26ClN3O5S

Molecular Weight

497.94

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Fernandes MA, et al. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. J Biochem Mol Toxicol. 2004;18 (3) :162-169.|[3]Heo R, et al. The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps. Life Sci. 2021;283:119868.|[4]Qiu Y, et al. Glyburide Regulates UCP1 Expression in Adipocytes Independent of KATP Channel Blockade. iScience. 2020;23 (9) :101446.|[5]Golstein PE, et al. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999;437 (5) :652-660.|[6]Zhou J, et al. Glibenclamide-Induced Autophagy Inhibits Its Insulin Secretion-Improving Function in β Cells. Int J Endocrinol. 2019;2019:1265175.